The Alzheimer’s disease brain homogenates that induced these alterations accelerated the occurrence of β-amyloid and tau lesions in transgenic mouse models of β-amyloid or tau. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.